Zimbabwe has rejected a significant US healthcare agreement worth 367 million US dollars (£272m) spanning five years due to Washington's insistence on confidential biological samples.
The decision came to light following a government memo from December was disclosed, which showed President Emmerson Mnangagwa deemed the deal was "lopsided".
An official representative later clarified that the US was requesting genetic material for research and commercial gain but was unwilling to share the benefits from future treatments.
"We must now begin the difficult and regrettable task of ending our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated more than $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has appealed for further negotiations to secure a deal agreeable to both sides so the country's critical HIV programme can proceed.
Broader Context
This development comes after a comparable situation in Kenya, where a high court halted a related deal with the US following concerns were filed about the safety of Kenyans' health data.
Since returning to the presidency recently, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
The agency had managed aid for the US government, but Trump stated its expenditure was "inefficient" and his government was pursuing government-to-government deals to enhance transparency and accountability.
Based on reports, 16 African countries have to date agreed to these new health pacts, representing over $18.3bn in new funding.
Specifics of the Declined Deal
The funds for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation could have provided extraordinary benefits for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment via American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Our nation was requested to surrender its biological resources and data for a long time, with no corresponding promise of benefiting from any medical innovations – such as new medicines or tests – that might be developed from that shared data," he stated.
"Effectively, our nation would provide the raw materials for scientific discovery without any assurance that the final treatments would be accessible to our people if a future disease outbreak emerge."
National Interest and Global Health
Mangwana further said that the American exit from the global health body and its pursuit of one-on-one deals were upending systems already established via the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system designed to manage potential global health emergencies.
"This framework is intended to ensure that when a country provides its data, the resulting advantages – such as medicines and cures – are distributed fairly, not commercialised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to continued dialogue with our American counterparts on how future co-operation could be designed in a way that honours the independence and interests of both nations."
Medical Community Reaction
Medical experts said it recognised the government's concerns, but suggested that talks need to persist considering much of the nation's HIV programmes were funded by external financing.
"In cases where technical issues arise, such as those involving information security or agreement terms, these can often be addressed through technical clarification and negotiated safeguards," the group added.
The halted deal highlights the complex tensions between accepting much-needed foreign assistance and protecting local interests in an increasingly data-driven world.